Physician profile
Meri Muminovic
NPI 1942706916
$6,460.22
in general payments reported to CMS, 2019-2025
27 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $16.61 · 2021: $472 · 2022: $1,335 · 2023: $1,521 · 2024: $1,775 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,846 · Education: $399 · Consulting Fee: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,845.74 |
| Education | $399.48 |
| Consulting Fee | $129.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $988.53 | 2019-2025 | Imfinzi, Tagrisso |
| Tempus Ai, INC | $568.40 | 2024-2025 | Xt Cdx |
| Coherus Oncology, INC. | $513.15 | 2022-2025 | Loqtorzi |
| E.R. Squibb & Sons, L.L.C. | $473.86 | 2019-2025 | Opdivo |
| Jazz Pharmaceuticals INC. | $420.07 | 2022-2023 | Zepzelca, Vyxeos |
| Pfizer INC. | $409.97 | 2024 | |
| Genentech USA, INC. | $371.03 | 2019-2024 | Tecentriq |
| Genzyme Corporation | $293.22 | 2022-2023 | |
| Amgen INC. | $270.06 | 2019-2021 | |
| Astellas Pharma US INC | $234.92 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $221.81 | 2024 | Rybrevant |
| Incyte Corporation | $206.60 | 2022-2023 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $192.06 | 2021-2023 | Libtayo |
| Janssen Biotech, INC. | $157.96 | 2024-2025 | Rybrevant |
| Gilead Sciences, INC. | $147.58 | 2025 | Trodelvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $124.99 | 2023 | Tepmetko |
| Springworks Therapeutics, INC. | $122.55 | 2024 | Ogsiveo |
| Blueprint Medicines Corporation | $121.87 | 2022 | |
| Rigel Pharmaceuticals, INC. | $121.04 | 2022 | |
| Eisai INC. | $107.95 | 2023 | |
| Lilly USA, LLC | $107.52 | 2024 | |
| Seagen INC. | $84.99 | 2023 | |
| Sanofi-Aventis U.S. LLC | $82.99 | 2023 | |
| Teleflex LLC | $34.11 | 2022 | |
| Array Biopharma INC | $28.76 | 2025 | Lorbrena, Xalkori, Mektovi |
| Legend Biotech USA INC. | $27.83 | 2024 | |
| Novartis Pharmaceuticals Corporation | $26.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meri Muminovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.